The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Allergan’s Truberzi (eluxadoline) in the European Union (EU) to treat adults with irritable bowel syndrome with diarrhoea (IBS-D).

Truberzi is a twice daily, oral medication used on adult patients suffering from IBS-D.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Allergan chief research and development officer David Nicholson said: “With this positive decision for Truberzi, Allergan is one step closer to bringing this innovative medication to IBS-D patients across Europe who are in desperate need of new treatment options.

“Once approved, Truberzi will join Constella (linaclotide) as the only licensed prescription medications proven to treat bothersome symptoms of IBS-D and irritable bowel syndrome with constipation (IBS-C) respectively.

"Truberzi has the potential to become the only licensed treatment for IBS-D in Europe providing a valuable, evidence-based treatment option for patients."

“Offering these effective treatment options to physicians and their patients underscores Allergan's commitment to helping address unmet needs in gastrointestinal diseases.”

See Also:

Results of two important trials demonstrated that the drug can effectively reduce abdominal pain and diarrhoea, which are the two major symptoms associated with the functional bowel disorder.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University of Leuven Belgium internal medicine professor Jan Tack said: “IBS-D can severely affect patient quality of life and in some cases it can be very debilitating.

“In the absence of effective medications, doctors and patients have had few options available beyond over-the-counter medicines, as well as diet and lifestyle modifications.

“Truberzi has the potential to become the only licensed treatment for IBS-D in Europe providing a valuable, evidence-based treatment option for patients.”

The European Commission is expected to give the final decision for the marketing authorisation of the drug within a few months.

If approved, Allergan is expected to launch this new medicine in Europe next year.